Citadel Advisors
ONCR

Citadel Advisors’s Oncorus, Inc. ONCR Stock Holding History

Citadel Advisors’s Portfolio ONCR Stock Details ONCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,100
Closed -$1.41K – 15631
2023
Q1 		$1.41K Sell
4,100
-89,300
-96% -$33.3K ﹤0.01% 14306
2022
Q4 		$23.7K Buy
93,400
+2,000
+2% +$1.14K ﹤0.01% 13004
2022
Q3 		$78K Sell
91,400
-95,600
-51% -$123K ﹤0.01% 11301
2022
Q2 		$236K Buy
187,000
+123,700
+195% +$168K ﹤0.01% 10343
2022
Q1 		$113K Buy
63,300
+52,700
+497% +$148K ﹤0.01% 12159
2021
Q4 		$56K Buy
+10,600
New +$82.1K ﹤0.01% 13190

Other funds holding ONCR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
YAL
Your Advocates Ltd Houston, Texas $328M AUM 19.81% 1-Year Est. Return

Citadel Advisors's ONCR Position: Q2 2023 in Review

Citadel Advisors sold out of Oncorus, Inc. (ONCR) in Q2 2023, closing a stake of 25,999 shares — an estimated $8.95K sold.

Citadel Advisors first reported a position in ONCR in Q4 2020 and held it in 10 quarters. The position peaked at $60.8M in Q4 2020. 4 funds tracked by Wall St. Rank hold ONCR as of Q2 2023.

  • Citadel Advisors reported no remaining Oncorus, Inc. position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 25,999 Oncorus, Inc. shares in Q2 2023, an estimated $8.95K.
  • Citadel Advisors first reported a position in Oncorus, Inc. in Q4 2020 and held it in 10 quarters.
  • Citadel Advisors's Oncorus, Inc. position peaked at $60.8M in Q4 2020.
  • 4 funds tracked by Wall St. Rank held Oncorus, Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.